

1 **Title:**
2 Contributing Factors to Advanced Brain Aging in Depression and Anxiety Disorders
3

4 **Working title:**
5 Brain age, somatic health, and depression and anxiety
6

7 Laura K.M. Han,¹ Hugo G. Schnack,² Rachel M. Brouwer,² Dick J. Veltman,¹ Nic J.A. van der Wee,^{3,4}
8 Marie-José van Tol,⁵ Moji Aghajani,¹ & Brenda W.J.H. Penninx.¹
9

10 ¹ Department of Psychiatry, Amsterdam University Medical Centers, Vrije Universiteit and GGZ inGeest, Amsterdam
11 Neuroscience, Amsterdam, The Netherlands.

12 ² Department of Psychiatry, UMCU Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.

13 ³ Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands.

14 ⁴ Department of Psychiatry, University Medical Center Leiden, Leiden, the Netherlands.

15 ⁵ Cognitive Neuroscience Center, University Medical Center Groningen, University of Groningen,
16 Groningen, the Netherlands.
17

18 **ABSTRACT (150 words)**
19

20 Brain aging has shown to be more advanced in patients with Major Depressive Disorder (MDD). This study
21 examines which factors underlie this older brain age. Adults aged 18-57 years from the Netherlands Study
22 of Depression and Anxiety underwent structural MRI. A pre-trained brain age prediction model based on
23 >2,000 samples from the ENIGMA consortium was applied to predict age in 65 controls and 220 patients
24 with current MDD and/or anxiety disorder. Brain-predicted age differences (brain-PAD) were calculated
25 (predicted brain age minus chronological age) and associated with clinical, psychological, and biological
26 factors. After correcting for antidepressant use, brain-PAD was significantly higher in MDD (+2.78 years)
27 and anxiety patients (+2.91 years) compared to controls. Findings further indicate unique contributions of
28 higher severity of somatic depression symptoms to advanced brain aging and a potential protective effect
29 of antidepressant medication (-2.53 years).
30
31

32 **Keywords:** brain age, depression, anxiety, somatic health, antidepressant use
33
34

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 INTRODUCTION

51
52 Depression and anxiety are common and often comorbid mental health disorders, and their effects can
53 broadly impact a person's life. There is a plethora of evidence showing poorer quality of life, functional
54 disability, and increased mortality burden in these patients (Bijl & Ravelli, 2000; Walker et al., 2015).
55 Depression and anxiety disorders further represent a risk factor for aging-related conditions (Penninx et al.,
56 2013; Révész et al., 2016; Verhoeven et al., 2015), as studies show consistent evidence for poorer somatic
57 and chronic disease profiles in these patient groups (Roy-Byrne et al., 2008), often with a premature onset.
58 Importantly, the incidence and burden of these disorders are a strain on society, which has an important
59 challenge to face in the coming years, as the number of people aged >65 is expected to reach 1.6 billion in
60 2050 (Ferrucci et al., 2019). Advancing mental health and well-being across the lifespan and into old age
61 should, therefore, be a major priority on the research agenda.

62
63 Multivariate pattern recognition techniques, and especially machine learning methods, have promoted a
64 steep increase in the development of ways to measure and quantify aging (Jylhava et al., 2017). Central to
65 this field is that multivariate (biological) patterns are utilized and integrated into a single score: the biological
66 age. Biological age can be derived from, for instance, omics-data (e.g. epigenetic clocks), but also clinical
67 biomarkers obtained from, for example, blood chemistries (Hägg et al., 2019). In the current study, we focus
68 on biological age based on a validated method of MRI-derived brain structure (Cole & Franke, 2017; Gaser
69 & Franke, 2019) with brain-predicted age difference (brain-PAD, predicted brain age minus chronological
70 age) (Cole et al., 2019) as the main outcome. This metric is relative to one's chronological age, such that
71 positive values indicate an older appearing brain, and negative values resemble a younger appearing brain
72 than normally expected at that age.

73
74 A handful of studies have investigated brain-PAD in depression, with studies showing +4.0 years
75 (Koutsouleris et al., 2014), as well as no significantly increased brain age (Besteher et al., 2019; Kaufmann
76 et al., 2019). Recent findings from the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA)
77 consortium using a more than ten-fold larger pooled sample of MDD patients than the largest previous
78 study suggest a 1.1 year higher brain-PAD in MDD patients as compared to controls (Han et al., 2019).

79 However, this difference did not seem to be driven by specific clinical characteristics (recurrent status,
80 remission status, antidepressant medication use, age of onset, or symptom severity). An important aspect
81 that remains relatively unknown is thus which underlying mechanisms cause the brain age metric to
82 advance in depression, and, despite the increase of brain age studies in the past decade, in general (Gaser
83 & Franke, 2019).

84
85 Large pooled datasets from global consortia offer the statistical power needed to detect small effect sizes
86 usually observed in MDD, but a limitation of consortium data is that its collection is commonly not
87 harmonized across all sites and cohorts. Here, we underline the complementary value of a more
88 homogeneous and clinically well-characterized sample from the Netherlands Study of Depression and
89 Anxiety (NESDA), to gain more insight into the observed brain-PAD difference between MDD patients and
90 controls. We extend prior work by exploring which specific symptom clusters (mood/cognition,
91 immunometabolic, somatic) of MDD are associated with brain-PAD. To the best of our knowledge, there
92 are currently no brain age studies in anxiety disorders, although higher brain-PAD has been observed in
93 posttraumatic stress disorder (Liang et al., 2019). Given the frequent co-occurrence and correlated
94 symptoms (Krueger & Markon, 2006) of depression and anxiety (i.e. family of internalizing disorders) (Caspi
95 et al., 2020), we also extend prior work by including patients with MDD and/or anxiety disorders in the
96 current study.

97
98 Evidence is starting to emerge that brain-PAD is associated with reduced mental and somatic health, such
99 as with stroke history, diabetes diagnosis, smoking, alcohol consumption, and some cognitive measures
100 (Cole, 2020), but also intrinsic measures such as genetic variants (Jonsson et al., 2019; Ning et al., 2020).
101 This study seeks to further address the research gaps, by examining whether three important biological
102 stress systems that are commonly found to be dysregulated in depression and anxiety disorders
103 (inflammation, hypothalamic pituitary adrenal [HPA]-axis, autonomic nervous system [ANS]), were
104 predictive of brain aging. Disruptions and dysregulations in these stress systems were hypothesized to
105 result in advanced brain aging across diagnostic groups. We further associated various clinical, lifestyle,
106 and somatic health indicators with the brain-PAD metric to identify unique contributing factors to brain aging.

107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148

RESULTS

Sample Characteristics

Demographics and assessed phenotypes of the current study sample can be found in **Table 1**. Briefly, the patient group consisted of patients with a current MDD diagnosis but no anxiety (28.2%), patients with a current anxiety disorder but no depression (30.5%), and patients with a current comorbid depression and anxiety disorder (41.4%). The patient group (mean 37.37 ± SD 10.20 years) was younger than the control group (mean 40.81 ± SD 9.78 years) and had fewer years of education (mean 14.28 ± SD 2.86 years in controls vs. mean 12.39 ± SD 3.19 in patients). Control and patient groups were similar in terms of male/female ratios, but not distributed equally between scan locations (Amsterdam, Leiden, Groningen) ($\chi^2_{(2)}=6.26, p=0.044$).

149 **Table 1: Participant Characteristics of Controls and Patients.**
150

Characteristic	N	Controls, N = 65 ₁	Patients, N = 220 ₁	p-value ₂
<i>Demographics</i>				
Age (years)	285	40.81 ± 9.78 (21.26-56.67)	37.37 ± 10.20 (17.76-57.17)	0.02
Female Sex	285	42 (65%)	152 (69%)	0.60
Education Level (years)	285	14.28 ± 2.86 (5.00-18.00)	12.39 ± 3.19 (5.00-18.00)	<0.001
Scanlocation	285			0.04
1		26 (40%)	66 (30%)	
2		27 (42%)	78 (35%)	
3		12 (18%)	76 (35%)	
<i>Clinical characteristics</i>				
Major depressive disorder			62 (28%)	
Anxiety disorder			67 (30%)	
Comorbid depression and anxiety			91 (41%)	
Total depression severity score	280	4 ± 4 (0-21)	23 ± 12 (1-57)	<0.001
Total anxiety severity score	278	2 ± 3 (0-11)	14 ± 10 (0-50)	<0.001
Mood/cognition symptom cluster	285	1.09 ± 0.13 (1.00-1.47)	1.86 ± 0.50 (1.00-3.27)	<0.001
Somatic depression symptom cluster	285	1.20 ± 0.21 (0.90-2.20)	1.64 ± 0.41 (0.80-2.80)	<0.001
Immunometabolic symptom cluster	285	1.11 ± 0.21 (0.80-1.80)	1.60 ± 0.48 (0.60-3.60)	<0.001
Childhood Trauma Index	285	1 ± 1 (0-8)	2 ± 2 (0-8)	<0.001
Recent negative life events	285	0.57 ± 0.83 (0.00-3.00)	0.89 ± 1.09 (0.00-3.00)	0.05
<i>Within patients</i>				
Antidepressant use	220		77 (35%)	

Duration of depressive symptoms (proportion of time in the past 4 years)	190		0.34 ± 0.28 (0.00-1.00)	
Duration of anxiety symptoms (proportion of time in the past 4 years)	192		0.42 ± 0.35 (0.00-1.00)	
Age of onset of depression (years)	191		23.75 ± 10.44 (4.00-54.00)	
Age of onset of anxiety (years)	170		18.15 ± 10.93 (4.00-52.00)	
<i>Somatic health</i>				
Body Mass Index (kg/m ²)	285	24.36 ± 3.73 (19.03-37.42)	25.14 ± 4.72 (18.04-42.21)	0.35
Number of somatic diseases	285	0 ± 1 (0-3)	0 ± 1 (0-3)	0.66
<i>Lifestyle</i>				
Alcohol intake (mean number of drinks per week)	285	6.2 ± 6.1 (0.0-25.0)	4.3 ± 6.5 (0.0-47.5)	0.01
Smoking behavior (cigarettes/day)	161	9.26 ± 7.61 (0.00-29.00)	12.56 ± 10.73 (0.00-70.00)	0.09
Physical activity (1,000 MET minutes per week)	271	3.8 ± 3.3 (0.3-16.5)	3.6 ± 3.5 (0.0-17.1)	0.19
<i>Inflammation</i>				
C-Reactive Protein (mg/l)	280	-0.03 ± 0.52 (-1.00-1.08)	0.11 ± 0.59 (-1.00-1.35)	0.17
Tumor Necrosis Factor-α (pg/ml)	279	-0.16 ± 0.26 (-1.00-0.63)	-0.12 ± 0.26 (-1.00-0.63)	0.39
Interleukin-6 (pg/ml)	280	-0.15 ± 0.31 (-1.12-0.57)	-0.14 ± 0.48 (-2.29-1.74)	0.89
<i>Autonomic Nervous System</i>				
Resting Heart Rate (bpm)	276	69 ± 8 (51-86)	68 ± 10 (44-96)	0.62
Respiratory Sinus Arrhythmia (ms)	276	51 ± 25 (14-130)	49 ± 26 (7-130)	0.59
Pre-injection Period (ms)	276	119 ± 17 (81-147)	119 ± 16 (75-168)	0.66
<i>HPA-axis</i>				
Cortisol Awakening Response Area under the curve with respect to the ground (nmol/l/hr)	197	0.57 ± 4.63 (-13.06-11.13)	2.44 ± 5.74 (-14.92-19.00)	0.10

Cortisol Awakening Response Area under the curve with respect to the increase (nmol/l/hr)	197	16.89 ± 4.88 (8.49-32.13)	18.51 ± 6.75 (5.36-37.97)	0.23
Evening cortisol (nmol/l)	207	5.05 ± 2.44 (2.12-13.33)	5.04 ± 2.43 (1.09-12.96)	0.90

¹ Statistics presented: mean ± SD (minimum-maximum); n (%)

² Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence

151
152

153 Brain age prediction performance

154 Using the ENIGMA brain age model (www.photon-ai.com/enigma_brainage) we obtained a correlation of
155 $r=0.73$ in the control subjects and $r=0.72$ in the patient group between predicted and chronological age, but
156 in both groups brain age predictions were overestimated (mean brain-PAD [SD]; 8.18 [7.27] years in
157 controls and 10.86 [7.73] years in patients). To correct for the offset, we calculated the mean brain-PAD in
158 the control group and subtracted these from all individual brain-PAD estimates. This correction resulted in
159 an R_2 of 0.45 and MAE of 5.97 (SD 4.09) years in controls, and R_2 of 0.36 and MAE of 6.73 (4.64) years in
160 patients (also see **Table 2** for model metrics). Of note, this linear correction does not affect subsequent
161 statistics. **Figure 1A** shows the unaffected correlation between predicted brain age (x-axis) and
162 chronological age (y-axis) in control subjects ($r=0.73$, $p<0.0001$) and in patients ($r=0.72$, $p<0.0001$). There
163 also was a well-known and commonly described age-bias (i.e. correlation between brain-PAD and age)
164 (Le, Kuplicki, McKinney, et al., 2018; Liang et al., 2019; Smith et al., 2019) in controls ($r=-0.32$, $p=0.01$) and
165 patients ($r=-0.37$, $p<0.0001$) in the current sample (**Figure 1B**), which was statistically dealt with by
166 including age as a predictor variable in further analyses (**Figure 1C**) (Le, Kuplicki, McKinney, et al., 2018).


167
168
169
170
171
172
173

174 **Table 2: Model metrics.**

	r	R2	MAE	SD	RMSE	Brain-PAD	SD
Controls	0.73	-0.26	9.01	6.19	10.91	8.18	7.27
Controls corrected	0.73	0.45	5.97	4.09	7.22	0	7.27
Patients	0.72	-0.71	11.38	6.95	13.32	10.86	7.73
Patients corrected	0.72	0.36	6.73	4.64	8.17	2.69	7.73

175 Performance metrics of the ENIGMA model applied to the NESDA data per
176 diagnostic group. r, Pearson's correlation coefficient; R₂, proportion of explained
177 variance; MAE, mean absolute error in years; SD, standard deviation; RMSE, root
178 mean squared error; Brain-PAD, mean brain predicted age difference in years
179 (predicted age - actual age). Corrected metrics reflect brain-PAD estimates - mean
180 brain-PAD_{controls}.

181




182
 183 **Figure 1: Brain age prediction.** (A) Correlation between predicted brain age and chronological age in
 184 controls ($r=0.73$, $R_2=0.45$, $p<0.0001$) and patients ($r=0.72$, $R_2=0.36$, $p<0.0001$). Of note, predicted brain
 185 age reflects estimates corrected for the offset (brain age_{corrected} = brain age - (brain-PAD - mean brain-
 186 PAD_{controls}). (B) There was a residual effect of age on the brain-PAD outcome in controls ($r=-0.32$, $p=0.01$)
 187 and patients ($r=-0.37$, $p<0.0001$), (C) which was statistically corrected for by adding age as a covariate in
 188 all models.
 189

190 **Advanced brain aging in depression and anxiety disorders**

191 Using diagnostic status as a dichotomous between-group predictor we found that patients exhibited +1.75
192 years higher brain-PAD than controls, but this difference did not reach statistical significance (Cohen's
193 $d=0.24$). Within the patient group only, we found no significant associations with the age of onset of illness
194 or duration of symptoms of either MDD or anxiety. However, brain-PAD was significantly lower in
195 antidepressants (AD) using patients compared to AD-free patients ($b=-2.58$ years, $p=0.01$), but not control
196 subjects ($b=0.59$ years, $p=0.65$) (**Figure 2**). Given the significant difference in brain-PAD between AD-free
197 and AD-using patients, we included AD status as an additional covariate when comparing controls to the
198 patient group, resulting in significantly higher brain-PAD in patients (+2.63 year [SE 1.10 year], Cohen's
199 $d=0.34$, 95% CI 0.06-0.62). We also added AD status as an additional covariate in a model to compare
200 controls against specific MDD, anxiety, or comorbid patient groups (the proportion of subjects using AD in
201 specific diagnostic groups was marginally different, $\chi^2=5.91$, $p=0.052$). This revealed significantly higher
202 brain-PAD in MDD (+2.78 years, Cohen's $d=0.25$, 95 % CI -0.10-0.60, $p=0.04$) and anxiety patients (+2.91
203 years, Cohen's $d=0.27$, 95% CI -0.08-0.61, $p=0.03$), and a similar effect in the comorbid MDD and anxiety
204 group (+2.23 years, Cohen's $d=0.21$, 95% CI 0.10-0.53) although only marginally significant ($p=0.08$)
205 (**Table 3**). There were no post-hoc differences in brain-PAD corrected for AD use between specific patient
206 groups (MDD vs. anxiety vs. comorbid patients; P 's>0.46, Cohen's d 's <0.07).

207



208
209 **Figure 2: Brain-PAD differences between controls, antidepressant using (AD-using) and**
210 **antidepressant-naive (AD-free) patients.** AD-free patients showed significantly higher brain-PAD
211 compared to AD-using patients (+2.58 year [SE 1.02 year], Cohen's $d=0.36$, 95% CI 0.09-0.64) and controls
212 (+2.63 year [SE 1.10 year], Cohen's $d=0.31$, 95% CI 0.01-0.60). Brain-PAD estimates (in years) were
213 residualized for age, sex, education level (years) and two dummy variables for scanlocation.

214

215

216

217 **Table 3: Advanced brain aging in depression and anxiety with correction for antidepressant use.**
 218

Ref	Predictor	b	SE	t value	P	Cohen's d	SE	95% CI
Controls	Any patient	2.63	1.10	2.39	0.02	0.34	0.14	0.06-0.62
	MDD	2.78	1.32	2.11	0.04	0.25	0.18	-0.09-0.6
	Anxiety	2.91	1.31	2.22	0.03	0.27	0.17	-0.08-0.61
	Comorbid MDD and anxiety	2.23	1.28	1.74	0.08	0.21	0.16	-0.11-0.53


219 Age, sex, education level (years) and two dummy variables for scanlocation were included in all models. Antidepressant
 220 status was additionally included as covariate.
 221

222 To gain more insight into the differences in brain-PAD between AD-free and AD-using patients, we post-
 223 hoc calculated a derived daily dose by dividing the AD mean daily dose by the daily dose recommended by
 224 the World Health Organization (also see (Licht et al., 2008)). Brain-PAD was not significantly negatively
 225 associated with a derived daily dose of antidepressants in n=74 patients (b=-0.91 year, p=0.50)
 226 (**Supplementary Figure S1**). Of note, we excluded three subjects from this analysis as these AD-using
 227 patients were using Venlafaxine at doses higher than 150 mg/day, acting as a dual serotonin and
 228 norepinephrine reuptake inhibitor rather than acting as a Selective Serotonin Reuptake Inhibitor (SSRI) only
 229 (Debonnel et al., 2007). Based on the above findings, both diagnostic and AD status were included in the
 230 multivariate model to test unique brain-PAD contributions.

231
 232 **Selection of significant associations with clinical variables in all participants**

233 Using a dimensional approach based on symptoms rather than diagnosis, we found that higher brain-PAD
 234 was associated with higher total depression (b=0.07 year per unit change on the Inventory of Depressive
 235 Symptoms, p=0.03) and anxiety severity scores (b=0.11 year per unit change on the Beck's Anxiety
 236 Inventory, p=0.01) across all participants (**Figure 3A-B**). No significant associations were found for the
 237 mood/cognition (b=0.89 year per unit increase on the average sum score, p=0.27, **Figure 3C**) or
 238 immunometabolic symptom clusters of depression (b=0.45 year per unit increase on the average sum
 239 score, p=0.62, **Figure 3D**), but higher brain-PAD was strongly associated with more somatic symptoms of

240 depression ($b=4.03$ year per unit increase on the average sum score, $p<0.0001$, **Figure 3E**). There were
241 no significant associations between brain-PAD and childhood trauma exposure ($b=0.23$ year per unit
242 change on the childhood trauma index, $p=0.26$) or recent negative life events ($b=0.35$ year per negative life
243 event, $p=0.39$).
244



245
246
247 **Figure 3: Brain-PAD associations with symptom severity.** (A) Advanced brain aging was associated
248 with overall higher total depressive symptoms ($b=0.07$ years per unit increase on the Inventory of
249 Depressive Symptoms, $p=0.03$), (B) total anxiety symptoms ($b=0.11$ years per unit increase on the Beck's
250 Anxiety Inventory, $p=0.01$), but not specifically with (C) the mood/cognition ($b=0.89$ years per unit increase
251 on average sum score, $p=0.27$) or (D) immunometabolic ($b=0.45$ years per unit increase on the average
252 sum score, $p=0.62$) symptom cluster. The association in (A) seemed to be driven mostly by (E) a specific
253 cluster of somatic symptoms in MDD ($b=4.03$ years per unit increase on the average sum score, $p<0.0001$).
254 Brain-PAD estimates (in years) were residualized for age, sex, education level (years) and two dummy
255 variables for scanlocation.
256

257
258
259
260
261


262 **Selection of significant associations with somatic health in all participants**

263 Higher brain-PAD was associated with both higher BMI ($b=0.23$ year per kg/m^2 , $p=0.02$, **Figure 4**), as well
264 as the number of somatic diseases under medical treatment ($b=1.45$ year per somatic disease, $p=0.03$).
265 However, the latter association became non significant if those with >2 chronic diseases ($n=4$) were
266 truncated to two chronic diseases ($b=1.29$ year per somatic disease, $p=0.08$).

267

268

269



270

271 **Figure 4: Brain-PAD associations with somatic health.** Each increase of 1 kg/m^2 in BMI leads to +0.23
272 years of added brain aging ($p=0.02$). Brain-PAD estimates (in years) were residualized for age, sex,
273 education level (years) and two dummy variables for scanlocation.

274

275

276

277 **No associations with lifestyle or biological stress variables**

278 There were no significant associations with any of the lifestyle variables (smoking, alcohol, physical activity)
279 or biological stress variables (inflammatory markers, ANS, HPA-axis). An overview of the separate linear
280 regressions can be found in **Table 4**.

281

282

283 **Table 4: Overview of the brain-PAD associations with predictors of interest.**

Assessment	Predictor	b	SE	t value	P
<i>Clinical</i>	Depressive symptom severity	0.07	0.03	2.16	0.03
	Anxiety symptom severity	0.11	0.04	2.50	0.01
	Mood/cognition symptoms	0.89	0.81	1.10	0.27
	Somatic depression symptoms	4.03	1.04	3.87	<0.00001
	Immunometabolic symptoms	0.45	0.92	0.49	0.62
	Childhood trauma index	0.23	0.20	1.13	0.26
	Negative life events	0.35	0.41	0.86	0.39
<i>Within patients</i>	Antidepressant use	-2.58	1.02	-2.54	0.01
	Duration of depressive symptoms	-0.20	1.97	-0.10	0.92
	Duration of anxiety symptoms	-0.88	1.55	-0.56	0.57
	Age of onset of depression	0.04	0.06	0.61	0.55
	Age of onset of anxiety	0.01	0.05	0.09	0.93
<i>Somatic health</i>	BMI	0.23	0.10	2.31	0.02
	Number of somatic diseases	1.29	0.72	1.79	0.08
<i>Lifestyle</i>	Alcohol (mean drinks per week)	-0.09	0.07	-1.33	0.19
	Smoking (cigarettes per day)	-0.07	0.05	-1.26	0.21
	Physical exercise (MET-minutes)	-0.06	0.13	-0.48	0.63
<i>Inflammation</i>	CRP	0.57	0.76	0.75	0.46

	TNF- α	0.10	1.65	0.06	0.95
	IL6	0.60	0.98	0.61	0.54
ANS	Resting HR	0.08	0.05	1.51	0.13
	RSA	-0.01	0.02	-0.46	0.65
	PEP	-0.04	0.03	-1.45	0.15
HPA-axis	AUCi	-0.04	0.10	-0.34	0.74
	AUCg	-0.04	0.09	-0.42	0.67
	Evening	0.18	0.23	0.76	0.45

284
 285 Age, sex, education level (years) and two dummy variables for scanlocation were included in all models. BMI, Body
 286 Mass Index; MET-minutes, ;CRP, C-reactive protein; TNF- α , Tumor Necrosis Factor- α ; IL6, Interleukin-6; ANS,
 287 autonomic nervous system; HR, heart rate; RSA, respiratory sinus arrhythmia; PEP, pre-ejection period; AUCi, cortisol
 288 awakening response: area under the curve with respect to the increase; AUCg, cortisol awakening response: area
 289 under the curve with respect to the ground; Evening, Evening Cortisol.

292 **Multivariable model**

293 To characterize the unique contributions of the selected significant predictors on the brain-PAD outcome,
 294 we included diagnostic status (control vs. patient), MDD and anxiety symptom scores, BMI, AD use, and
 295 the number of somatic diseases under treatment as predictors in a stepwise regression model with forward
 296 selection. Thus, predictors were successively added to an intercept-only model (Akaike's Information
 297 Criterion [AIC] = 1115.81), only adding regression coefficients if they improved model fit (i.e. lower AIC).
 298 Using this method, we found that the best subset of variables to explain brain-PAD consisted of somatic
 299 depression symptoms and AD use (AIC=1098.79). In sum, unique contributions to brain-PAD were
 300 observed for the somatic depression symptom cluster (b=4.21 year per unit increase on average sum score,
 301 p<0.0001) and AD use (b=-2.53 year, p=0.007) (**Table 5**).

302

303

304
305
306

Table 5: Result of stepwise regression model with forward selection of brain-PAD contributors.

N	Selected predictors	b	95% CI	SE	t value	P
285	Somatic depression symptoms	4.21	2.25 to 6.16	1.00	4.22	<0.0001
	AD Use	-2.53	-4.36 to -0.70	0.93	-2.72	0.007

307 Current model with lowest AIC=1098.79 compared to intercept-only model AIC=1115.81. The brain-PAD outcome
308 was residualized for age, sex, educational level (years) and two dummy variables for scanlocation.
309

310

311 DISCUSSION

312

313 The current study used a validated brain age prediction model to show that the previously observed findings
314 of older appearing brains in MDD patients was associated with symptom severity and BMI. Moreover,
315 antidepressant (AD) users exhibited similar average brain-PAD as control subjects, whereas those that
316 were AD-free showed older appearing brains. Correcting for AD-use, we also showed that not only MDD
317 patients, but also patients with anxiety disorder exhibited older appearing brains compared to controls.
318 Surprisingly, there were no significant associations with lifestyle or biological stress systems. A multivariable
319 model showed unique contributions of somatic depression symptom severity and AD-use on brain-PAD.

320

321 To the best of our knowledge, we are the first to report advanced brain aging in anxiety disorders (i.e.
322 generalized anxiety disorder, panic disorder, social anxiety disorder) with an estimated +2.91 years on
323 average, compared to controls, when correcting for AD use. This is consistent with the literature describing
324 comparable effect sizes with respect to structural brain alterations in social anxiety disorder (Cohen's
325 $d=0.20$) (Bas-Hoogendam et al., 2017), and other anxiety-related disorders such as post-traumatic stress
326 disorder (PTSD) (Cohen's $d=-0.17$) (Logue et al., 2018), with PTSD patients also showing advanced brain-
327 PAD without correction for AD (Liang et al., 2019). This observation may potentially offer an explanation as
328 to why clinical anxiety is associated with an increased risk of dementia, even independent from depression
329 (Santabárbara et al., 2019), although further evidence is needed. The lack of any significant post-hoc
330 differences between specific diagnostic groups can likely be explained due to, amongst others, the high

331 genetic correlation between the disorders (Brainstorm Consortium et al., 2018), shared environmental risks,
332 and overlapping personality traits of patients with depression and anxiety disorders (Ruscio & Khazanov,
333 2017).

334
335 The most clinically relevant finding was that AD-using patients showed a similar brain age to controls, but
336 not to AD-free patients, irrespective of specific depressive or anxiety disorder. This finding was previously
337 overlooked in consortium data, presumably due to a lack of more detailed information on lifetime use,
338 dosage and duration of use of AD (Han et al., 2019), highlighting the complementary values of well-
339 characterized local samples and large-scale consortia. The AD finding was particularly interesting as the
340 AD-using patients constituted a more severely depressed and anxious group as indicated by higher
341 symptom severities compared to AD-free patients, potentially suggesting compensatory or normalizing
342 mechanisms of AD, at least on the brain-PAD metric. This accords with earlier work reporting brain-PAD
343 associations with therapeutic drugs, suggesting neuroprotective effects of Lithium treatment in bipolar
344 disorder patients (vs. no Lithium) (Van Gestel et al., 2019) and ibuprofen (vs. placebo) in healthy
345 participants in a exploratory randomized controlled trial (Le, Kuplicki, Yeh, et al., 2018). Yet, it remains
346 unclear if and to what extent the brain age protective mechanisms overlap with, for example, increased
347 neural progenitor cells (Boldrini et al., 2012), brain-derived neurotrophic factor (BDNF) (Castrén & Kojima,
348 2017), or other serotonergic neuroplasticity processes implicated in AD use (Kraus et al., 2017), or,
349 alternatively, whether neuropharmacology affects the MRI signal (Cousins et al., 2013). Brain-PAD was not
350 positively associated with the duration of symptoms (either MDD or anxiety), suggesting that the AD effect
351 was not driven by the duration of the disease and did not seem to be progressive. Taken together, these
352 findings may suggest an age-related neuroprotective effect of AD, but interpretative caution is warranted
353 as the current study was cross-sectional in nature and the dose-response association with AD not
354 statistically significant. We also did not find associations with physical activity, while a previous study found
355 an association between brain-PAD and the daily number of flights of stairs climbed (Steffener et al., 2016).
356 Future clinical interventions are needed to examine the short and long-term effects of antidepressants and
357 physical activity on biological aging, an objective currently pursued by the MOod treatment with
358 antidepressants or running (MOTAR) study (Lever-van Milligen et al., 2019).

359
360 There were no associations with the cumulative childhood trauma index or the number of recent negative
361 life events, different from the impact that adverse childhood experience commonly has on other biological
362 age indicators such as telomere length (Aas et al., 2019), or epigenetic aging (Wolf et al., 2018), albeit with
363 small effects. Future studies with larger samples may potentially be more sensitive in picking up
364 associations between brain-PAD and childhood trauma. However, taken together, the current study found
365 that advanced brain aging was more associated with current disease states, likely related to current
366 symptom severity, rather than the result of cumulative exposure (i.e. no association with childhood trauma
367 history, age of onset of illness, duration of symptoms) or traits.

368
369 Furthermore, Cole and colleagues (2020) found significant associations between brain-PAD and several
370 biomedical (e.g. blood pressure, diabetes, stroke) and lifestyle variables (e.g. smoking status, alcohol intake
371 frequency), but not BMI, in the UK Biobank (Cole, 2020), albeit with a different, multi-modal brain age
372 prediction model but in a much larger sample size (>14,000 subjects). Although the current findings with
373 somatic health broadly support previously associated diabetes (Franke et al., 2013) and stroke findings in
374 UK Biobank, as well as the null-finding with respect to physical activity, we did not identify associations with
375 smoking or alcohol behavior (Franke et al., 2013). More work is needed in terms of identifying unique or
376 shared robust contributors to the brain-PAD metric, converging evidence across and between datasets,
377 processing methods, and populations. Other previous studies, however, also identified associations with
378 BMI (Franke et al., 2014) and here we show that an increase of 1 kg/m² in BMI leads to +0.23 years of
379 added brain aging, although not independent from depression or anxiety symptom severity. A previous
380 study did show such an independent effect for obesity and first-episode schizophrenia (Kolenic et al., 2018),
381 but here the obese group only constituted of 13% of the total current sample. Furthermore, each increase
382 of 1 of the average sum score (range 0.80-4.00) of somatic depression symptoms, resulted in +4.20 years
383 of added brain aging, independent from AD use. The somatic symptom cluster studied here consisted of
384 items tapping into sleep, psychomotor, and other bodily symptom problems (see **Supplement** for all
385 individual items within each cluster). This emphasizes the need to prevent and improve both mental and
386 somatic conditions to promote healthy brain aging in psychiatric populations.

387
388 Surprisingly, none of the biological stress systems considered in the current study were predictive of brain
389 aging, despite the strong association between brain-PAD and somatic symptoms. This suggests that the
390 biological dysregulations that commonly link depression to somatic health (Penninx et al., 2013), were not
391 directly contributing to advanced brain aging. On the other hand, it might indicate that the brain-PAD metric
392 is more responsive to psychological stressors, rather than biological stressors. With respect to the
393 inflammatory markers, it might be possible that blood levels of inflammatory markers do not accurately
394 mirror central neuroimmune levels, although there is some evidence that C-Reactive Protein (CRP)
395 measured peripherally also reflects central inflammation, at least in MDD (Felger et al., 2018). Alternatively,
396 a different potential biological mechanism that may explain the observed advanced brain aging in
397 depression and anxiety disorders is metabolic dysregulation. Future studies could characterize the brain-
398 PAD metric in more detail with respect to metabolic factors (e.g. blood pressure, triglycerides, cholesterol),
399 as these are well-established risk factors for unfavorable somatic conditions (Eckel et al., 2005; Esposito
400 et al., 2012; Mottillo et al., 2010; Profenno et al., 2010) and frequently co-occur with depression (Pan et al.,
401 2012).

402
403 Given the richness of the current dataset, we additionally computed post-hoc intercorrelations between the
404 brain-PAD metric and other available biological age indicators in NESDA. Briefly, we found low, non-
405 significant (P 's>0.13), correlations between brain-PAD, and three omics-based clocks (epigenetic,
406 transcriptomic, metabolomic) and telomere length (with Pearson r in the range of -0.03 to 0.15,
407 **Supplementary Figure S2**). Surprisingly, brain-PAD was negatively associated with the proteomic clock
408 ($r=-0.24$, $p=0.02$) after correcting for age (albeit in a greatly reduced overlapping sample of $N=98$). Only a
409 handful of studies have compared multiple biological age indicators side-by-side (Belsky et al., 2018;
410 Jansen et al., 2020; Kim et al., 2017; Murabito et al., 2018), but the current findings support most work
411 showing the very little overlap between biological clocks from different types of data (Hägg et al., 2019).
412 However, the small but significant negative correlation between brain and proteomic aging suggests a
413 further study with more focus on the interplay between this peripheral and central proxy of aging is needed.

414 Aging remains a multifaceted and complex process that may manifest differently across multiple biological
415 levels and tissues.

416

417 **Limitations**

418 It is important to mention that our sample had low statistical power to detect (some of) the relatively small
419 effect sizes in the current study. At present, the large within-group variance of brain-PAD lacks utilitarian
420 validity in a clinical context. We, therefore, emphasize the need for both methodological (i.e. brain age
421 models) as well as epidemiological replication (i.e. other and larger samples) to test the robustness of
422 effects. Another limitation is reflected by the lack of insights into the causal pathways implicated in advanced
423 brain aging, given the cross-sectional nature of the study. However, a major strength is that we used a pre-
424 established reference curve for healthy brain aging that has further potential for benchmarking, as the
425 ENIGMA MDD working group encourages local research samples like ours to examine more detailed
426 phenotypes that were not available within the consortium. Also important to note is that the effects of
427 multivariate brain aging patterns (Cohen's $d=0.34$, between controls and all patients) was higher or
428 comparable to other biological aging indicators (e.g. telomere length [Cohen's $d=0.12$] (Verhoeven et al.,
429 2013), epigenetic aging [$d=0.14$] (Han et al., 2018), biological markers (e.g. BDNF [$d=0.23$] (Molendijk et
430 al., 2011), cortisol [$d=0.15-0.25$] (Vreeburg et al., 2009), CRP [$d=0.15$] (Howren et al., 2009)), and, most
431 importantly, neuroimaging markers (e.g. hippocampal volume [$d=-0.14$] (Schmaal et al., 2015)), in other or
432 (partly) overlapping samples.

433

434 **Conclusion**

435 In summary, advanced brain aging in patients with MDD and anxiety seems to be most strongly associated
436 with somatic health indicators such as somatic depressive symptomatology, BMI, and the number of chronic
437 diseases under medical treatment. We also revealed that antidepressant medication use was associated
438 with lower brain-PAD, potentially suggesting that its use may have a protective effect on the age-related
439 structural gray matter alterations observed in patients with MDD and anxiety, an effect previously
440 overlooked in consortium data. Our results, therefore, emphasize the importance and complementary value
441 of smaller, yet more homogeneous, datasets with harmonized data collection and well-characterized clinical

442 phenotyping, compared to the large-scale consortium data needed for statistical power. Randomized
443 clinical trials are needed to confirm whether advanced brain aging can be halted or reversed, by intervening
444 on the cross-sectional somatic health indicators identified here, in pursuit of the characterization of a
445 complex multifaceted process such as brain aging.

446 **METHODS AND MATERIALS**

447

448

449 **Subjects**

450 A subsample of subjects of the Netherlands Study of Depression and Anxiety (NESDA) were included for
451 the MRI substudy (total N=301). Twelve participants were excluded due to poor image quality, two because
452 of claustrophobia, one control subject due to high depression rating (Montgomery Asberg Depression
453 Rating Scale score >8), and one due to the large time difference between the psychiatric and biological and
454 MRI measurements (total excluded, N=16). For the current study, we therefore included N=65 controls
455 (65% female, aged 21-55) and N=220 patients with a current depressive and/or anxiety disorder (69%
456 female, aged 18-57). The current study was approved by the ethical review boards of the three participating
457 centers (Amsterdam, Groningen, Leiden) and informed consent of all participants was obtained.

458

459 **Image processing and analysis**

460 Magnetic resonance imaging (MRI) data were obtained using three independent 3T Philips MRI scanners
461 (Philips Healthcare, Best, The Netherlands) located at different participating centers. Scanners were
462 equipped with a SENSE 8-channel (Leiden University Medical Center and University Medical Center
463 Groningen) and a SENSE 6-channel (Academic Medical Center) receiver head coil (Philips Healthcare).
464 Standardized image segmentation and feature extraction protocols, using the FreeSurfer processing
465 software, developed by the ENIGMA consortium were used ([http://enigma.ini.usc.edu/protocols/imaging-
466 protocols/](http://enigma.ini.usc.edu/protocols/imaging-protocols/)) to extract 153 features from regions of interest, including the volumes of 14 subcortical gray
467 matter regions (bilateral nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and
468 thalamus) and the 2 lateral ventricles, cortical thickness and surface area from 68 cortical regions, and
469 total intracranial volume (ICV). Segmentations were statistically examined for outliers and the FreeSurfer
470 feature was excluded if it was >2.698 standard deviations away from the global mean. However, if a sample

471 was a statistical outlier, but visual inspection showed that it was properly segmented, it was kept in the
472 dataset.

473

474 **FreeSurfer brain age prediction model**

475 We used a publicly available brain age model (https://www.photon-ai.com/enigma_brainage/) that was
476 trained to predict age from $77 \left(\frac{\text{left} + \text{right hemisphere features}}{2} \right)$ and ICV) FreeSurfer features (for more
477 detail, see (Han et al., 2019). Briefly, the Ridge Regression coefficients learned from 952 male and 1,236
478 female control subjects (aged 18-75 years) from the ENIGMA MDD working group were applied to the
479 features of the current samples (N=285). Of note, NESDA was not part of the development of this model.
480 The model's generalization performance was assessed by calculating several metrics: a) the correlation
481 between predicted brain age and chronological age, b) the amount of chronological age variance explained
482 by the model (R^2), c) the mean absolute error (MAE) between predicted brain age and chronological age,
483 and d) Root Mean Squared Error (RMSE).

484

485 **Diagnostic ascertainment**

486 Participants in the current study included control subjects (no lifetime history of psychiatric disorders) and
487 patients with a current depression and/or current anxiety disorder (i.e. generalized anxiety disorder, panic
488 disorder, social anxiety disorder) within a 6-month recency. The Composite International Diagnostic
489 Interview (CIDI version 2.1) was used as a diagnostic instrument to ascertainment (Wittchen, 1994).

490

491 **Clinical assessment**

492 We examined several clinical variables as predictors, including a) depressive symptoms as measured by
493 the summary score of the Inventory for Depressive Symptoms (IDS) at time of scanning (Rush et al., 1996),
494 but also b) three separate validated clusters of depressive symptoms (mood/cognition, somatic, and
495 immunometabolic symptoms) (Wardenaar et al., 2010), c) anxiety symptoms as measured by the summary
496 score of the Beck Anxiety Inventory (BAI) at time of scanning (Fydrich et al., 1992), d) cumulative childhood
497 trauma index (Hovens et al., 2010) (before the age of 16) as measured by a childhood trauma interview,
498 and e) recent negative life events in the past year as measured with the Brugha questionnaire (Brugha &

499 Cragg, 1990). Within the patients only, we also investigated associations with: a) duration of symptoms, b)
500 age of onset of illness, and c) antidepressant medication use (selective serotonin reuptake inhibitors (ATC
501 code N06AB) and other antidepressants (ATC codes N06AF, N06AG, N06AX). See **Supplement** for full
502 details.

503

504 **Somatic health assessment**

505 Body Mass Index (BMI) was assessed during an interview by dividing a person's weight (in kilogram [kg])
506 by the square of their height (in meter [m]). The number of self-reported current somatic diseases (heart
507 disease, epilepsy, diabetes, osteoarthritis, cancer, stroke, intestinal disorders, ulcers, and lung-, liver-, and
508 thyroid disease) for which participants received medical treatment was counted.

509

510 **Lifestyle assessment**

511 Smoking status was expressed by calculating the number of cigarettes smoked per day. Alcohol
512 consumption was expressed as the mean number of drinks consumed per week, measured by the AUDIT
513 (Bush et al., 1998). Physical activity was assessed using the International Physical Activity Questionnaire
514 (IPAQ) and expressed in total metabolic equivalent (MET) minutes per week (Craig et al., 2003).

515

516 **Biological stress assessment**

517 We included predictors from three major biological stress systems: a) the immune-inflammatory system (C-
518 reactive protein [CRP], Interleukin-6 (IL6), and tumor necrosis factor- α (TNF- α), b) the hypothalamic
519 pituitary adrenal (HPA)-axis (cortisol awakening response [CAR] and evening cortisol), and c) the
520 autonomic nervous system (ANS: heart rate, respiratory sinus arrhythmia [RSA] and pre-ejection period
521 [PEP]). Details can be found in **Supplement**.

522

523 **Statistical analysis**

524

525 All statistical analyses were performed using R version 3.5.3 (R Core Team, 2019). First, we used linear
526 regressions to examine brain-PAD differences between the control and patient groups and tested brain-
527 PAD associations with several clinical characteristics within the patients only (i.e. duration of symptoms,

528 age of onset of illness, AD use). Second, we used separate linear regression models with brain-PAD as
529 measured outcome and variables of interest as a predictor to explore and select significant contributors in
530 all participants irrespective of diagnostic group. Finally, stepwise regression with forward selection was
531 used to successively add significant contributors to an intercept-only model, starting with the variable that
532 explained most variance and stopping if the model fit did not improve anymore. The best subset of variables
533 leading to the best model fit (i.e. lowest Aikake's Information Criterion [AIC]) were selected to examine
534 unique contributions to brain-PAD. Inflammatory predictors were \log_e -transformed due to highly skewed
535 distributions and subsequently corrected for fasting status and anti-inflammatory medication use. ANS
536 predictors were corrected for fasting status, heart medication use, and mean arterial blood pressure. HPA
537 predictors were corrected for fasting status, awakening time, variable indicating whether it was a working
538 day or not, and season. All biological stress markers >3 *sd away from the mean were winsorized. Age, sex,
539 education level (years), and two dummy variables for scan location were included as predictor variables in
540 all models. Analyses were tested two-sided and findings were considered statistically significant at $p<0.05$.
541 All b regression coefficients from all models may be interpreted as added brain aging in years in response
542 to each unit increase of the predictor.

543

544 **ACKNOWLEDGEMENTS AND DISCLOSURES**

545 The infrastructure for the Netherlands Study of Depression and Anxiety (<https://www.nesda.nl>) is funded
546 through the Geestkracht program of the Netherlands Organization for Health Research and Development
547 (Zon-MW, Grant number 10-000-1002) and is supported by participating universities and mental health care
548 organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ
549 Rivierduinen, University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific
550 Institute for Quality of Healthcare [IQ healthcare], and the Netherlands Institute of Mental Health and
551 Addiction [Trimbos Institute]). LKMH and BWJHP were partly supported through the European Lifebrain
552 consortium. BWJHP has received research funding (not related to the current paper) from Boehringer
553 Ingelheim and Jansen Research. The other authors report no biomedical financial interests or potential
554 conflicts of interest.

555

556 **Data availability**

557 Data sources are not available due to privacy issues, but we highly value scientific collaboration. Therefore,
558 in principle, NESDA data are available to all scientific researchers working at non-commercial research
559 organizations worldwide. Researchers can request either existing data for data analyses or bioanalysis.
560 Please visit the online data overview for an extensive overview of the available data and NESDA's current
561 output (www.nesda.nl). The used brain age prediction model can be found on [https://www.photon-](https://www.photon-ai.com/enigma_brainage/)
562 [ai.com/enigma_brainage/](https://www.photon-ai.com/enigma_brainage/).

563

564 **ARTICLE INFORMATION**

565 Address correspondence to Laura K.M. Han, MSc, Department of Psychiatry, Amsterdam University
566 Medical Centers, Location VUmc, Oldenaller 1, 1081 HJ Amsterdam, The Netherlands; E-mail:
567 l.han@amsterdamumc.nl

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595 **REFERENCES**

- 596 Aas, M., Elvsåshagen, T., Westlye, L. T., Kaufmann, T., Athanasiu, L., Djurovic, S., Melle, I., van der Meer,
597 D., Martin-Ruiz, C., Steen, N. E., Agartz, I., & Andreassen, O. A. (2019). Telomere length is associated
598 with childhood trauma in patients with severe mental disorders. *Translational Psychiatry, 9*(1), 97.
- 599 *Anatomical Therapeutic Chemical (ATC) Classification Index: Alphabetically Sorted According to*
600 *Nonproprietary Drug Name ; Only ATC 5th Levels are Included.* (n.d.). WHO Collaborating Centre for
601 Drug Statistics and Methodology.
- 602 Bas-Hoogendam, J. M., van Steenbergen, H., Nienke Pannekoek, J., Fouche, J.-P., Lochner, C., Hattingh,
603 C. J., Cremers, H. R., Furmark, T., Månsson, K. N. T., Frick, A., Engman, J., Boraxbekk, C.-J.,
604 Carlbring, P., Andersson, G., Fredrikson, M., Straube, T., Peterburs, J., Klumpp, H., Phan, K. L., ...
605 van der Wee, N. J. A. (2017). Voxel-based morphometry multi-center mega-analysis of brain structure
606 in social anxiety disorder. *NeuroImage. Clinical, 16*, 678–688.
- 607 Belsky, D. W., Moffitt, T. E., Cohen, A. A., Corcoran, D. L., Levine, M. E., Prinz, J. A., Schaefer, J., Sugden,
608 K., Williams, B., Poulton, R., & Caspi, A. (2018). Eleven Telomere, Epigenetic Clock, and Biomarker-
609 Composite Quantifications of Biological Aging: Do They Measure the Same Thing? *American Journal*
610 *of Epidemiology, 187*(6), 1220–1230.
- 611 Besteher, B., Gaser, C., & Nenadić, I. (2019). Machine-learning based brain age estimation in major
612 depression showing no evidence of accelerated aging. In *Psychiatry Research: Neuroimaging* (Vol.
613 290, pp. 1–4). <https://doi.org/10.1016/j.psychresns.2019.06.001>
- 614 Bijl, R. V., & Ravelli, A. (2000). Current and residual functional disability associated with psychopathology:
615 findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Psychological*
616 *Medicine, 30*(3), 657–668.
- 617 Boldrini, M., Hen, R., Underwood, M. D., Rosoklija, G. B., Dwork, A. J., Mann, J. J., & Arango, V. (2012).
618 Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in
619 major depression. *Biological Psychiatry, 72*(7), 562–571.
- 620 Brainstorm Consortium, Anttila, V., Bulik-Sullivan, B., Finucane, H. K., Walters, R. K., Bras, J., Duncan, L.,
621 Escott-Price, V., Falcone, G. J., Gormley, P., Malik, R., Patsopoulos, N. A., Ripke, S., Wei, Z., Yu, D.,
622 Lee, P. H., Turley, P., Grenier-Boley, B., Chouraki, V., ... Murray, R. (2018). Analysis of shared

- 623 heritability in common disorders of the brain. *Science*, 360(6395).
624 <https://doi.org/10.1126/science.aap8757>
- 625 Brugha, T. S., & Cragg, D. (1990). The List of Threatening Experiences: the reliability and validity of a brief
626 life events questionnaire. *Acta Psychiatrica Scandinavica*, 82(1), 77–81.
- 627 Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT Alcohol
628 Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. *Archives*
629 *of Internal Medicine*, 158(16), 1789–1795.
- 630 Caspi, A., Houts, R. M., Ambler, A., Danese, A., Elliott, M. L., Hariri, A., Harrington, H., Hogan, S., Poulton,
631 R., Ramrakha, S., Rasmussen, L. J. H., Reuben, A., Richmond-Rakerd, L., Sugden, K., Wertz, J.,
632 Williams, B. S., & Moffitt, T. E. (2020). Longitudinal Assessment of Mental Health Disorders and
633 Comorbidities Across 4 Decades Among Participants in the Dunedin Birth Cohort Study. *JAMA*
634 *Network Open*, 3(4), e203221.
- 635 Castrén, E., & Kojima, M. (2017). Brain-derived neurotrophic factor in mood disorders and antidepressant
636 treatments. *Neurobiology of Disease*, 97(Pt B), 119–126.
- 637 Cole, J., Franke, K., & Cherbuin, N. (2019). Quantification of the biological age of the brain using
638 neuroimaging. In *Healthy ageing and longevity*. Biomarkers of Human Aging.
- 639 Cole, J. H. (n.d.). *Multi-modality neuroimaging brain-age in UK Biobank: relationship to biomedical, lifestyle*
640 *and cognitive factors*. <https://doi.org/10.1101/812982>
- 641 Cole, J. H., & Franke, K. (2017). Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers.
642 *Trends in Neurosciences*, 40(12), 681–690.
- 643 Cousins, D. A., Aribisala, B., Nicol Ferrier, I., & Blamire, A. M. (2013). Lithium, gray matter, and magnetic
644 resonance imaging signal. *Biological Psychiatry*, 73(7), 652–657.
- 645 Craig, C. L., Marshall, A. L., Sjöström, M., Bauman, A. E., Booth, M. L., Ainsworth, B. E., Pratt, M., Ekelund,
646 U., Yngve, A., Sallis, J. F., & Oja, P. (2003). International physical activity questionnaire: 12-country
647 reliability and validity. *Medicine and Science in Sports and Exercise*, 35(8), 1381–1395.
- 648 Debonnel, G., Saint-André, E., Hébert, C., de Montigny, C., Lavoie, N., & Blier, P. (2007). Differential
649 physiological effects of a low dose and high doses of venlafaxine in major depression. *The International*
650 *Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale*

- 651 *Neuropsychopharmacologicum*, 10(1), 51–61.
- 652 Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. *The Lancet*, 365(9468),
653 1415–1428.
- 654 Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012). Metabolic syndrome and risk of
655 cancer: a systematic review and meta-analysis. *Diabetes Care*, 35(11), 2402–2411.
- 656 Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A.,
657 Feinberg, R., Tansey, M. G., & Miller, A. H. (2018). What does plasma CRP tell us about peripheral
658 and central inflammation in depression? In *Molecular Psychiatry*. [https://doi.org/10.1038/s41380-018-](https://doi.org/10.1038/s41380-018-0096-3)
659 0096-3
- 660 Ferrucci, L., Gonzalez-Freire, M., Fabbri, E., Simonsick, E., Tanaka, T., Moore, Z., Salimi, S., Sierra, F., &
661 de Cabo, R. (2019). Measuring biological aging in humans: A quest. *Aging Cell*, e13080.
- 662 Franke, K., Gaser, C., Manor, B., & Novak, V. (2013). Advanced BrainAGE in older adults with type 2
663 diabetes mellitus. *Frontiers in Aging Neuroscience*, 5(DEC), 1–9.
- 664 Franke, K., Ristow, M., & Gaser, C. (2014). Gender-specific impact of personal health parameters on
665 individual brain aging in cognitively unimpaired elderly subjects. *Frontiers in Aging Neuroscience*,
666 6(MAY), 1–14.
- 667 Fydrich, T., Dowdall, D., & Chambless, D. L. (1992). Reliability and validity of the Beck Anxiety Inventory.
668 *Journal of Anxiety Disorders*, 6(1), 55–61.
- 669 Gaser, C., & Franke, K. (2019). 10 years of BrainAGE as an neuroimaging biomarker of brain aging: What
670 insights did we gain? *Frontiers in Neurology*, 10, 789.
- 671 Hägg, S., Belsky, D. W., & Cohen, A. A. (2019). Developments in molecular epidemiology of aging.
672 *Emerging Topics in Life Sciences*, 3(4), 411–421.
- 673 Han, L. K. M., Aghajani, M., Clark, S. L., Chan, R. F., Hattab, M. W., Shabalin, A. A., Zhao, M., Kumar, G.,
674 Xie, L. Y., Jansen, R., Milaneschi, Y., Dean, B., Aberg, K. A., van den Oord, E. J. C. G., & Penninx, B.
675 W. J. H. (2018). Epigenetic Aging in Major Depressive Disorder. *The American Journal of Psychiatry*,
676 175(8), 774–782.
- 677 Han, L. K. M., Dinga, R., Hahn, T., Ching, C., Eyler, L., Aftanas, L., Aghajani, M., Aleman, A., Baune, B.,
678 Berger, K., Brak, I., Filho, G. B., Carballado, A., Connolly, C., Couvy-Duchesne, B., Cullen, K.,

- 679 Dannlowski, U., Davey, C., Dima, D., ... Schmaal, L. (2019). Brain Aging in Major Depressive Disorder:
680 Results from the ENIGMA Major Depressive Disorder working group. In *bioRxiv* (p. 560623).
681 <https://doi.org/10.1101/560623>
- 682 Hovens, J. G. F. M., Wiersma, J. E., Giltay, E. J., Van Oppen, P., Spinhoven, P., Penninx, B. W. J. H., &
683 Zitman, F. G. (2010). Childhood life events and childhood trauma in adult patients with depressive,
684 anxiety and comorbid disorders vs. controls. *Acta Psychiatrica Scandinavica*, *122*(1), 66–74.
- 685 Howren, M. B., Lamkin, D. M., & Suls, J. (2009). Associations of depression with C-reactive protein, IL-1,
686 and IL-6: a meta-analysis. *Psychosomatic Medicine*, *71*(2), 171–186.
- 687 Jansen, R., Verhoeven, J. E., Han, L. K. M., Aberg, K. A., van den Oord, E., Milaneschi, Y., & Penninx, B.
688 (2020). An integrative study of five biological clocks in somatic and mental health. *eLife* (under review).
- 689 Jonsson, B. A., Bjornsdottir, G., Thorgeirsson, T. E., Ellingsen, L. M., Walters, G. B., Gudbjartsson, D. F.,
690 Stefansson, H., Stefansson, K., & Ulfarsson, M. O. (2019). Brain age prediction using deep learning
691 uncovers associated sequence variants. *Nature Communications*, *10*(1), 5409.
- 692 Jylhava, J., Pedersen, N. L., & Hagg, S. (2017). Biological Age Predictors. *EBioMedicine*, *21*, 29–36.
- 693 Kaufmann, T., van der Meer, D., Doan, N. T., Schwarz, E., Lund, M. J., Agartz, I., Alnæs, D., Barch, D. M.,
694 Baur-Streubel, R., Bertolino, A., Bettella, F., Beyer, M. K., Bøen, E., Borgwardt, S., Brandt, C. L.,
695 Buitelaar, J., Celius, E. G., Cervenka, S., Conzelmann, A., ... Westlye, L. T. (2019). Common brain
696 disorders are associated with heritable patterns of apparent aging of the brain. *Nature Neuroscience*,
697 *22*(10), 1617–1623.
- 698 Kim, S., Myers, L., Wyckoff, J., Cherry, K. E., & Jazwinski, S. M. (2017). The frailty index outperforms DNA
699 methylation age and its derivatives as an indicator of biological age. *GeroScience*, *39*(1), 83–92.
- 700 Kolenic, M., Franke, K., Hlinka, J., Matejka, M., Capkova, J., Pausova, Z., Uher, R., Alda, M., Spaniel, F.,
701 & Hajek, T. (2018). Obesity, dyslipidemia and brain age in first-episode psychosis. *Journal of*
702 *Psychiatric Research*, *99*(vember 2017), 151–158.
- 703 Koutsouleris, N., Davatzikos, C., Borgwardt, S., Gaser, C., Bottlender, R., Frodl, T., Falkai, P., Riecher-
704 Rössler, A., Möller, H. J., Reiser, M., Pantelis, C., & Meisenzahl, E. (2014). Accelerated brain aging in
705 schizophrenia and beyond: A neuroanatomical marker of psychiatric disorders. *Schizophrenia Bulletin*,
706 *40*(5), 1140–1153.

- 707 Kraus, C., Castrén, E., Kasper, S., & Lanzenberger, R. (2017). Serotonin and neuroplasticity--links between
708 molecular, functional and structural pathophysiology in depression. *Neuroscience and Biobehavioral*
709 *Reviews*, *77*, 317–326.
- 710 Krueger, R. F., & Markon, K. E. (2006). Reinterpreting comorbidity: a model-based approach to
711 understanding and classifying psychopathology. *Annual Review of Clinical Psychology*, *2*, 111–133.
- 712 Le, T. T., Kuplicki, R. T., McKinney, B. A., Yeh, H.-W., Thompson, W. K., Paulus, M. P., & Tulsa 1000
713 Investigators. (2018). A Nonlinear Simulation Framework Supports Adjusting for Age When Analyzing
714 BrainAGE. *Frontiers in Aging Neuroscience*, *10*, 317.
- 715 Le, T. T., Kuplicki, R., Yeh, H. W., Aupperle, R. L., Khalsa, S. S., Simmons, W. K., & Paulus, M. P. (2018).
716 Effect of Ibuprofen on BrainAGE: A Randomized, Placebo-Controlled, Dose-Response Exploratory
717 Study. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 1–8.
- 718 Lever-van Milligen, B. A., Verhoeven, J. E., Schmaal, L., van Velzen, L. S., Révész, D., Black, C. N., Han,
719 L. K. M., Horsfall, M., Batelaan, N. M., van Balkom, A. J. L. M., van Schaik, D. J. F., van Oppen, P., &
720 Penninx, B. W. J. H. (2019). The impact of depression and anxiety treatment on biological aging and
721 metabolic stress: study protocol of the MOod treatment with antidepressants or running (MOTAR)
722 study. *BMC Psychiatry*, *19*(1), 425.
- 723 Liang, H., Zhang, F., & Niu, X. (2019). Investigating systematic bias in brain age estimation with application
724 to post-traumatic stress disorders. *Human Brain Mapping*, *10*, 1.
- 725 Licht, C. M. M., de Geus, E. J. C., Zitman, F. G., Hoogendijk, W. J. G., van Dyck, R., & Penninx, B. W. J.
726 H. (2008). Association between major depressive disorder and heart rate variability in the Netherlands
727 Study of Depression and Anxiety (NESDA). *Archives of General Psychiatry*, *65*(12), 1358–1367.
- 728 Logue, M. W., van Rooij, S. J. H., Dennis, E. L., Davis, S. L., Hayes, J. P., Stevens, J. S., Densmore, M.,
729 Haswell, C. C., Ipser, J., Koch, S. B. J., Korgaonkar, M., Lebois, L. A. M., Peverill, M., Baker, J. T.,
730 Boedhoe, P. S. W., Frijling, J. L., Gruber, S. A., Harpaz-Rotem, I., Jahanshad, N., ... Morey, R. A.
731 (2018). Smaller Hippocampal Volume in Posttraumatic Stress Disorder: A Multisite ENIGMA-PGC
732 Study: Subcortical Volumetry Results From Posttraumatic Stress Disorder Consortia. *Biological*
733 *Psychiatry*, *83*(3), 244–253.
- 734 Molendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R.

- 735 C. O., & Elzinga, B. M. (2011). Serum levels of brain-derived neurotrophic factor in major depressive
736 disorder: state–trait issues, clinical features and pharmacological treatment. *Molecular Psychiatry*,
737 16(11), 1088–1095.
- 738 Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg,
739 M. J. (2010). The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.
740 *Journal of the American College of Cardiology*, 56(14), 1113–1132.
- 741 Murabito, J. M., Zhao, Q., Larson, M. G., Rong, J., Lin, H., Benjamin, E. J., Levy, D., & Lunetta, K. L. (2018).
742 Measures of Biologic Age in a Community Sample Predict Mortality and Age-Related Disease: The
743 Framingham Offspring Study. *The Journals of Gerontology. Series A, Biological Sciences and Medical*
744 *Sciences*, 73(6), 757–762.
- 745 Ning, K., Zhao, L., Matloff, W., Sun, F., & Toga, A. W. (2020). Association of relative brain age with tobacco
746 smoking, alcohol consumption, and genetic variants. *Scientific Reports*, 10(1), 10.
- 747 Pan, A., Keum, N., Okereke, O. I., Sun, Q., Kivimaki, M., Rubin, R. R., & Hu, F. B. (2012). Bidirectional
748 association between depression and metabolic syndrome: a systematic review and meta-analysis of
749 epidemiological studies. *Diabetes Care*, 35(5), 1171–1180.
- 750 Penninx, B. W. J. H., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013). Understanding the somatic
751 consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC*
752 *Medicine*, 11, 129.
- 753 Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010). Meta-analysis of Alzheimer’s disease risk
754 with obesity, diabetes, and related disorders. *Biological Psychiatry*, 67(6), 505–512.
- 755 Révész, D., Verhoeven, J. E., Milaneschi, Y., & Penninx, B. W. J. H. (2016). Depressive and anxiety
756 disorders and short leukocyte telomere length: mediating effects of metabolic stress and lifestyle
757 factors. *Psychological Medicine*, 46(11), 2337–2349.
- 758 Roy-Byrne, P. P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L.,
759 Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., & Stein, M. B. (2008). Anxiety disorders and
760 comorbid medical illness. *General Hospital Psychiatry*, 30(3), 208–225.
- 761 Ruscio, A. M., & Khazanov, G. K. (2017). Anxiety and depression. *The Oxford Handbook of Mood*
762 *Disorders*, 313–324.

- 763 Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996). The Inventory of Depressive
764 Symptomatology (IDS): psychometric properties. *Psychological Medicine*, 26(3), 477–486.
- 765 Santabàrbara, J., Lopez-Anton, R., de la Cámara, C., Lobo, E., Gracia-García, P., Villagrasa, B., Bueno-
766 Notivol, J., Marcos, G., & Lobo, A. (2019). Clinically significant anxiety as a risk factor for dementia in
767 the elderly community. *Acta Psychiatrica Scandinavica*, 139(1), 6–14.
- 768 Schmaal, L., Veltman, D. J., van Erp, T. G. M., Sämann, P. G., Frodl, T., Jahanshad, N., Loehrer, E.,
769 Tiemeier, H., Hofman, A., Niessen, W. J., Vernooij, M. W., Ikram, M. a., Wittfeld, K., Grabe, H. J.,
770 Block, A., Hegenscheid, K., Völzke, H., Hoehn, D., Czisch, M., ... Hibar, D. P. (2015). Subcortical brain
771 alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working
772 group. *Molecular Psychiatry*, October 2014, 1–7.
- 773 Smith, S. M., Vidaurre, D., Alfaro-Almagro, F., Nichols, T. E., & Miller, K. L. (2019). *Estimation of Brain Age*
774 *Delta from Brain Imaging*. <https://doi.org/10.1101/560151>
- 775 Steffener, J., Habeck, C., O'Shea, D., Razlighi, Q., Bherer, L., & Stern, Y. (2016). Differences between
776 chronological and brain age are related to education and self-reported physical activity. *Neurobiology*
777 *of Aging*, 40(February), 138–144.
- 778 Van Gestel, H., Franke, K., Petite, J., Slaney, C., Garnham, J., Helmick, C., Johnson, K., Uher, R., Alda,
779 M., & Hajek, T. (2019). Brain age in bipolar disorders: Effects of lithium treatment. *The Australian and*
780 *New Zealand Journal of Psychiatry*, 53(12), 1179–1188.
- 781 Verhoeven, J. E., Révész, D., Epel, E. S., Lin, J., Wolkowitz, O. M., & Penninx, B. W. J. H. (2013). Major
782 depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study.
783 *Molecular Psychiatry*, May, 1–7.
- 784 Verhoeven, J. E., Révész, D., Van Oppen, P., Epel, E. S., Wolkowitz, O. M., & Penninx, B. W. J. H. (2015).
785 Anxiety disorders and accelerated cellular ageing. *British Journal of Psychiatry*, 206(5), 371–378.
- 786 Vreeburg, S. A., Hoogendijk, W. J. G., van Pelt, J., Derijk, R. H., Verhagen, J. C. M., van Dyck, R., Smit, J.
787 H., Zitman, F. G., & Penninx, B. W. J. H. (2009). Major depressive disorder and hypothalamic-pituitary-
788 adrenal axis activity: results from a large cohort study. *Archives of General Psychiatry*, 66(6), 617–626.
- 789 Walker, E. R., McGee, R. E., & Druss, B. G. (2015). Mortality in mental disorders and global disease burden
790 implications: a systematic review and meta-analysis. *JAMA Psychiatry*, 72(4), 334–341.

791 Wardenaar, K. J., van Veen, T., Giltay, E. J., de Beurs, E., Penninx, B. W. J. H., & Zitman, F. G. (2010).
792 Development and validation of a 30-item short adaptation of the Mood and Anxiety Symptoms
793 Questionnaire (MASQ). *Psychiatry Research*, 179(1), 101–106.

794 Wittchen, H. U. (1994). Reliability and validity studies of the WHO-Composite International Diagnostic
795 Interview (CIDI): A critical review. *Journal of Psychiatric Research*, 28(1), 57–84.

796 Wolf, E. J., Maniates, H., Nugent, N., Maihofer, A. X., Armstrong, D., Ratanatharathorn, A., Ashley-Koch,
797 A. E., Garrett, M., Kimbrel, N. A., Lori, A., Va Mid-Atlantic Mirecc Workgroup, Aiello, A. E., Baker, D.
798 G., Beckham, J. C., Boks, M. P., Galea, S., Geuze, E., Hauser, M. A., Kessler, R. C., ... Logue, M. W.
799 (2018). Traumatic stress and accelerated DNA methylation age: A meta-analysis.
800 *Psychoneuroendocrinology*, 92, 123–134.

801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830